Healthcare / Medical Instruments & SuppliesStockholm
$220.00
+1.20 (+0.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $59.9M · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.5B
P/E
79.1x
↑EV/EBITDA
66.8x
↑ROE
16.4%
↑Gross Margin
92.6%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+52.9%
FCF CAGR
—
FCF margin
18.4%
FCF / Net income
1.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.17B · net income $142.2M · FCF $216.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.17B | $1.17B | $898.7M | $591.1M | $328.8M |
| Net Income | $142.2M | $142.2M | $133.8M | $245.0M | $-68.2M |
| EBITDA | $214.4M | $214.4M | $185.8M | $28.9M | $-54.3M |
| EPS | 2.13 | 2.13 | 2.01 | 3.74 | -1.06 |
| Gross Margin | 92.6% | 92.6% | 92.6% | 91.5% | 90.5% |
| Operating Margin | 23.6% | 23.6% | 16.4% | 3.8% | -20.6% |
| Net Margin | 12.1% | 12.1% | 14.9% | 41.5% | -20.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.03 | 0.06 |
| Current Ratio | 5.13 | 5.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $216.1M | $216.1M | $59.9M | $-24.3M | $-50.3M |
| Returns | |||||
| ROE | 16.4% | 16.4% | 18.4% | 44.9% | -25.3% |
| Valuation | |||||
| P/E | 79.14 | 79.14 | 199.10 | 51.84 | — |
| EV/EBITDA | 66.80 | 66.80 | 142.36 | 434.34 | — |
| P/B | 16.94 | 16.94 | 36.64 | 23.33 | 19.05 |
| Growth & Yield | |||||
| Revenue Growth | 30.7% | 30.7% | 52.0% | 79.8% | — |
| EPS Growth | 6.0% | 6.0% | -46.3% | 452.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
109.3%
EPS terminal req.
$19.52
Spread vs growth
-103.3%
5Y implied EPS CAGR
61.8%
EPS terminal req.
$23.62
Spread vs growth
-55.8%
10Y implied EPS CAGR
33.4%
EPS terminal req.
$38.04
Spread vs growth
-27.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.7%
Start / end P/E
126.9x → 103.3x
EPS bridge
2.01 → 2.13
Residual
-1.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.